Leading Companies Fueling Growth and Innovation in the Lung Cancer Screening Market

Lung cancer remains one of the most critical health challenges worldwide, and early detection is essential for improving patient outcomes. The lung cancer screening market is gaining momentum as healare providers increasingly adopt advanced technologies and personalized approaches. Here's a detailed look at the market size, key players, trends, and segment insights shaping the future of lung cancer screening.

Projected Expansion of the Lung Cancer Screening Market by 2030
The lung cancer screening market is anticipated to experience significant growth, reaching a value of $5.24 billion by 2030. This expansion corresponds to a compound annual growth rate (CAGR) of 9.5%. Several factors contribute to this positive outlook, such as wider adoption of AI-assisted diagnostic workflows, growth in population-based screening programs, heightened emphasis on personalized risk assessments, increased investments in early detection technologies, and supportive healare policies promoting screening initiatives. Key market trends during this period include greater incorporation of low-dose CT screening programs, expanding AI integration in imaging analysis, enhanced focus on screening high-risk groups, growth of preventive oncology efforts, and stronger prioritization of early lung cancer detection.

Download a free report of the lung cancer screening market report:
https://www.thebusinessresearchcompany.com/report/lung-cancer-screening-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Companies Driving the Lung Cancer Screening Market
The competitive landscape of the lung cancer screening market is shaped by a number of prominent firms, including Abbott Laboratories Inc., Canon Inc., Siemens Healthineers AG, Koninklijke Philips N.V., GE Healare Technologies Inc., Quest Diagnostics Incorporated, Shimadzu Corporation, NeoGenomics Laboratories Inc., Freenome Holdings Inc., Biodesix Inc., Lunit Inc., Infervision, Riverain Technologies, VisionGate, Delfi Diagnostics Inc., Hologic Inc., Fujifilm Holdings Corporation, United Imaging Healare Co. Ltd., Samsung Medison Co. Ltd., Carestream Health Inc., Analogic Corporation, and Toshiba Medical Systems Corporation.

Partnerships Enhancing Early Lung Cancer Detection in India
In May 2025, Johnson & Johnson MedTech, a US-based healare technology company, formed a strategic partnership with Qure.ai to improve early lung cancer detection across India. Through this collaboration, Johnson & Johnson MedTech aims to strengthen its AI-driven diagnostic tools and broaden access to early-stage lung cancer screening by establishing AI-powered Incidental Pulmonary Nodule (IPN) detection clinics in major Indian hospitals. QURE AI TECHNOLOGIES PRIVATE LIMITED, an India-headquartered company, specializes in AI-based medical imaging solutions focused on automated lung nodule detection, triage, and IPN management using X-ray and CT technologies.

View the full lung cancer screening market report:
https://www.thebusinessresearchcompany.com/report/lung-cancer-screening-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Trends Guiding the Lung Cancer Screening Market's Future
Innovations are playing a crucial role in shaping the lung cancer screening landscape. For instance, companies are increasingly concentrating on developing advanced products such as plant-based polysaccharide absorbable hemostat powders designed to improve clotting efficiency and safety during surgeries. These powders, derived from refined natural starch, quickly absorb blood to trigger clotting and are fully bioresorbable, eliminating the need for removal post-application.

For example, in July 2023, Baxter International Inc., a US healare company, launched PERCLOT in the United States-a starch-based passive absorbable hemostatic powder intended for patients with intact coagulation to manage mild surgical bleeding. This product rapidly absorbs water to form a gelled adhesive matrix that acts as a mechanical barrier against bleeding while encouraging the accumulation of platelets, red blood cells, and coagulation proteins. PERCLOT complements Baxter's existing hemostat portfolio by reducing the need for blood transfusions, lowering complications, and decreasing overall healare expenses.

Detailed Segmentation of the Lung Cancer Screening Market
The lung cancer screening market is categorized into several segments to better understand its scope and applications:

1) Diagnosis Type:
- Low Dose Spiral Computed Tomography Scan
- Chest X-Ray

2) Cancer Type:
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer

3) Age Group:
- 50 And Older
- Below 50

4) End-User:
- Hospitals And Clinics
- Diagnostic Centers
- Other End-Users

Further divisions include:

- For Low Dose Spiral Computed Tomography Scan: Screening, Diagnostic, Follow-Up
- For Chest X-Ray: Posterior Anterior, Lateral, Portable

These classifications provide a comprehensive understanding of the market's structure, highlighting areas where technological advancements and targeted screenings can have the greatest impact.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.